Sigyn Therapeutics, Inc. (OTCQB: SIGY), developer of CardioDialysis, a next-generation blood purification technology, disclosed today that researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). The findings, published in the journal Science Translational Medicine and highlighted by Scientific American, suggest that the blood-brain barrier may remain compromised for decades after an athlete's retirement from contact sports.
When the blood-brain barrier is compromised, inflammatory molecules and pathogenic toxins in the bloodstream can enter the brain, triggering neuroinflammation and the accumulation of tau protein, a hallmark of CTE. The study observed that former athletes appeared to exist in a persistent state of chronic hyperinflammation. This adds to evidence that systemic inflammation is a key driver of neuroinflammation in disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
CardioDialysis, which enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, is uniquely positioned as a potential adjunct therapy for neuroinflammatory conditions. The company is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury (TBI), while its lead clinical indication remains cardiovascular disease.
"It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease," stated Sigyn Therapeutics CEO Jim Joyce. "The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain."
The Scientific American article, titled "Brain’s Protective Barrier Stays Leaky for Years after Playing Contact Sports," is available at Scientific American. Sigyn Therapeutics continues to develop CardioDialysis for applications in cardiovascular disease, sepsis, life-threatening viral infections, and neurological disorders associated with systemic inflammation.
